This page shows what was measured, who it was measured in, and what that does not settle.
What Sildenafil does in the body
Pulmonary arterial hypertension
From the FDA-approved label: The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
Where each sentence above came from
The recorded explanation is written in label language rather than for a beginner. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 105 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Enzyme
An enzyme is a protein that speeds up one chemical change.
A picture of it, and where the picture fails
An enzyme is like a machine on a production line doing one cut.
Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.
What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.
A catalytic protein that lowers the activation energy of a specific reaction.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Endurance
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
…Waiting for a reviewer4 registered performance measure of this kind.
∅Nothing in the sources checkedNo registered study lists a symptom measure for this goal.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Endurance
6 minute walk distance; vo2 peak; six minute walk distance in meters; endurance time
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
… Waiting for a reviewer
4 registered performance measure of this kind.
— Not recorded
Harms were not a registered measure for this goal.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Assess the impact of a sildenafil educational program versus usual care on subjects' satisfaction regarding their management of ED with sildenafil as assessed through the validated EDITS questionnnaire after 3 months of treatment
✗ The study did not show it
Who was studied
NCT00159848
How many people
8000
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Patient choice of treatment (either sildenafil or tadalafil) for use in the extension phase
✗ The study did not show it
Who was studied
NCT00547287
How many people
2760
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Pregnancy outcome
✗ The study did not show it
Who was studied
NCT06178523
How many people
900
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Change from baseline in the Self-esteem domain of the SEAR questionnaire
✗ The study did not show it
Who was studied
NCT00648596
How many people
780
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Time to Discontinuation of Randomized Treatment
✗ The study did not show it
Who was studied
NCT01122264
How many people
770
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
The clinical pregnancy rate
✗ The study did not show it
Who was studied
NCT03945812
How many people
665
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.1 registered measure of this kind. No reviewed result.
■What a body can do day to dayEvidence recorded. Walking, dressing, breathing, recovering.5 registered measures of this kind.
■Measured performanceEvidence recorded. How much was lifted, how far was run, how fast.5 registered measures of this kind.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.8 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse, Rat, Dog. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
vo2 peak
decrease in supine systolic blood pressure
blood pressure
24h urine volume
maximum plasma concentration
systolic blood pressure during the night
endurance time
time to reach maximum observed plasma concentration
trough plasma concentrations
maximum observed plasma concentration
Meaningful
Things that change how a life goes, not only a number.
6 minute walk distance
6 minute walk test
progression free survival
six minute walk distance in meters
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (26)
vary by protocol
potency rate at 2 years after surgery
safety
efficacy
flow mediated dilatation
carotid femoral pulse wave velocity
visual persistence
reaction time
oxygen consumption at 6 weeks
choice of treatment for use in the extension phase
choice of drug at visit 5
peak oxygen uptake during exercise
treatment related adverse events
cmax auc
adverse events
shim at 6 months after initial screening visit
area under the curve
adverse events and serious adverse events
left ventricular diastolic function
auclast
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
& USAGE Sildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when sildenafil tablets were added to background epoprostenol therapy [see Clinical Studies (14)].
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness have not been established in pediatric patients.”
US prescribing information · fbe75c2c-0aff-9ade-e053-6394a90a1ea4 · read 2026-08-30
On older people, the label states: “Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil resulting in approximately 84% and 107% higher plasma AUC values of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy young volunteers (18-45 years) [ see Clinical Pharmacology ( 12.3 ) ].”
US prescribing information · fbe75c2c-0aff-9ade-e053-6394a90a1ea4 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Sildenafil tablets are not indicated for use in females.”
US prescribing information · fbe75c2c-0aff-9ade-e053-6394a90a1ea4 · read 2026-08-30
On people with reduced liver function, the label states: “In volunteers with hepatic impairment (Child-Pugh Class A and B), sildenafil clearance was reduced, resulting in higher plasma exposure of sildenafil (47% for C max and 85% for AUC).”
US prescribing information · fbe75c2c-0aff-9ade-e053-6394a90a1ea4 · read 2026-08-30
On people with reduced kidney function, the label states: “No dose adjustment is required for mild (CLcr=50-80 mL/min) and moderate (CLcr=30-49 mL/min) renal impairment.”
US prescribing information · fbe75c2c-0aff-9ade-e053-6394a90a1ea4 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
Sold as tablet, for suspension, solution, suspension, given by the oral, intravenous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Reports sent to a regulator
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Sildenafil appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 3416 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
267 products list this as an active ingredient in the United States drug directory. 267 of them contain it and nothing else.
FDA National Drug Code directory · 72888-015 · read 2026-08-29
They are sold as film, for suspension, injection, solution, powder, powder, for suspension and tablet, taken intravenous and oral.
FDA National Drug Code directory · 72888-015 · read 2026-08-29
The regulator's established pharmacologic class for it is phosphodiesterase 5 inhibitor [epc] and phosphodiesterase 5 inhibitors [moa].
FDA National Drug Code directory · 72888-015 · read 2026-08-29
167 published labels name it as an active ingredient. 167 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · fbe75c2c-0aff-9ade-e053-6394a90a1ea4 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · fbe75c2c-0aff-9ade-e053-6394a90a1ea4 · read 2026-08-29
Sildenafil Citrate is oral at 3 DOSAGE FORMS AND STRENGTHS Sildenafil tablets, USP are supplied as green, oval-shaped, beveled edge, biconvex, film-coated tablets containing sildenafil citrate equivalent to 25 mg, 50 mg, or 100 mg of sildenafil., recorded as fda label in effect 2026-03-20 in the United States.
US prescribing information · fbe75c2c-0aff-9ade-e053-6394a90a1ea4 · read 2026-08-30
Recorded price in US: 0.05101–0.12762 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 100 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Recorded price in US: 0.27273 USD per one millilitre, across 9 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.
Questions worth asking
Which of the trials of Sildenafil studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Sildenafil are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
◇Read from sources, not yet reviewed
No traced study record is stored for this substance.
Built from stored sources by fixed rules. No reviewer has signed it off.
How many documents were read
166 documents were read for this substance.
RNAWiki source record
9 of them state the same halfLife, and they agree.
RNAWiki source record
166 of them state the same bioavailability, and they agree.
RNAWiki source record
9 of them state the same tMax, and they agree.
RNAWiki source record
166 of them state the same volumeOfDistribution, and they agree.
RNAWiki source record
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✗ Not passed
Safety mode resolved
No register row and no identity class settled the question.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
58 approved applications cover products containing this substance. The earliest was NDA020895, approved 19980327 to VIATRIS.
This order is fixed in code and does not count clicks or time on the page.
What is not here
6 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
The path through the body — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (14)
Q1
What did Sildenafil's largest trial (3337 people) and its longest (16 years) measure?
3337 people in Sildenafil's largest registered study, 16 years in its longest registered window, measuring Combined Outcome End-Point: all-cause mortality or hospital admission for heart failure, worsening of World Health Organization (WHO) functional class, or of the patient global assessment score. ClinicalTrials.gov · 2026-09-01
103 phase2, 102 phase4, 70 phase1, 70 phase3, 37 na, 13 na or unstated, 11 early phase1; NCT00223717; 2017-01. Last human test completed 2025, NCT06778330.
Interpretation These counts include studies where Sildenafil was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
103
phase4
102
phase1
70
phase3
70
na
37
na or unstated
13
2 more recorded rows
early phase1
11
Last recorded human testNCT06778330
2025-08-01
recorded 2026-09-01 · last checked 2026-09-04
Q2
From mouse to human: where has Sildenafil shown lifespan?
Interpretation Combined Outcome End-Point: all-cause mortality or hospital admission for heart failure, worsening of World Health Organization (WHO) functional class, or of… — the recorded outcome words.
Show the evidence
mouse
lifespan
rat
mechanism-only
dog
lifespan
humanNCT00862043
lifespan; Combined Outcome End-Point: all-cause mortality or hospital admission for heart failure, worsening of World Health Organization (WHO) functional class, or of the patient global assessment score; 369
"Change in clinical practice allowing chronic therapy at 6 weeks of age, incompatible with possibility of placebo beyond 6 weeks of age on study protocol"; 54 of 369 registered studies
Show the evidence
Trial
NCT00133679
terminated; "Change in clinical practice allowing chronic therapy at 6 weeks of age, incompatible with possibility of placebo beyond 6 weeks of age on study protocol"
NCT00141310
terminated; "Study prematurely discont'd 20-Apr-2006 after interim analysis suggested sample size could be reduced without losing power. No safety concerns led to decision."
NCT00145938
terminated; "Unable to complete study"
NCT00194597
terminated; "Illness of PI forced termination."
NCT00302211
terminated; "Terminated due to slow enrollment"
NCT00430716
terminated; "This study was terminated at the recommendation of an independent Data Monitoring Committee. The decision was not based on any safety concerns."
14 further recorded trials
NCT00452582
terminated; "Failure to recruit in expected time period."
NCT00492531
terminated; "Subjects on drug were more likely to have severe pain crises requiring hospitalization."
20 recorded entries; human; tablet, by mouth; also "Sildenafil 100mg", "Sildenafil (50 mg)", "Sildenafil 100 mg"
Show the evidence
human
NCT00137072
Viagra (Sildenafil Citrate) 100 mg
NCT00273416
Sildenafil 100mg
NCT00352482
Sildenafil (50 mg)
NCT00640458
Sildenafil 100 mg
NCT00692237
- Viagra 25 mg
NCT00692237
- Viagra 50 mg
14 more recorded rows
humanNCT00848497
tablet; Viagra® 25 mg tablet daily at night
humanNCT00904748
sildenafil citrate 100 mg CT
humanNCT00950404
tablet; Viagra 50 mg tablet
humanNCT01054001
sildenafil 100mg
humanNCT01054001
Viagra 100mg
humanNCT01091870
Sildenafil Citrate, 25 mg, 3 times a day.
humanNCT01091870
Sildenafil Citrate 50 mg, 3 times a day
humanNCT01637675
by mouth; 20 mg sildenafil citrate by mouth
humanNCT01637675
by mouth; sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth
humanNCT01941732
Sildenafil (Viagra (R)) 100 mg
humanNCT01948518
Oral sildenafil 20 mg
humanNCT01986673
5% Sildenafil Cream (SST-6006)
humanNCT01986673
Oral Sildenafil 50 mg
humanNCT02028598
Sildenafil citrate 100mg (Viagra Tab)
recorded 2026-09-01 · last checked 2026-09-04
Q5
More Sildenafil was worse in human: at what point?
U-shaped in human: "Herein, we have successfully modeled the U-shaped sildenafil dose-response in vitro and utilized this model to assess potential mechanisms of this dose-response relationship." Europe PMC · dose-response search · 2026-06-01
5 recorded sentences naming Sildenafil; U-shaped, dose-response, biphasic, dose response
Show the evidence
U-shapedPMID 31248114
"Herein, we have successfully modeled the U-shaped sildenafil dose-response in vitro and utilized this model to assess potential mechanisms of this dose-response relationship."
dose-response
PMID 42296271
"This dose-response network meta-analysis highlighted better efficacy with sildenafil (sildenafil 100 mg: odds ratio [OR] 9.06, sildenafil 50 mg: OR 7.90) in improving EF compared to that with placebo, followed by tadalafil (tadalafil 20 mg: OR 7.13, tadalafil 10 mg: OR 3.14), vardenafil (vardenafil 10 mg: OR 7.78), and avanafil (avanafil 200 mg: OR 3.42, avanafil 100 mg: OR 1.75)."
PMID 36678615
"The dose-response relationship of sildenafil effects on cardiac function is not completely elucidated."
biphasicPMID 31248114
"Adipocytes and liver cells were treated with leucine (0.5 mM) and different concentrations of sildenafil (1 nM to 100 µM). cAMP, cGMP, and P-AMPK protein expression were used to demonstrate the biphasic response for increasing concentrations of sildenafil."
dose responsePMID 23274729
"Regarding the effect of yohimbine and sildenafil on isolated rat corpus cavernosum, their cumulative dose response curves (3×10(-7), 3×10(-6) and 3×10(-5) M) were determined in corpus cavernosum strips isolated from normal rats and pre-contracted with phenylephrine (3×10(-6) M) were also assessed."
recorded 2026-06-01 · last checked 2026-09-04
Q6
Which of 24h urine volume, 6 minute walk distance and 6 minute walk test did Sildenafil's trials measure?
24h urine volume, 6 minute walk distance and 6 minute walk test lead 40 outcome terms across Sildenafil's trials. ClinicalTrials.gov · 2026-09-01
vo2 peak, safety, efficacy, 6 minute walk test, decrease in supine systolic blood pressure and blood pressure follow.
Show the evidence
vary by protocol
1
potency rate at 2 years after surgery
1
6 minute walk distance
1
vo2 peak
1
safety
1
efficacy
1
14 more recorded rows
6 minute walk test
1
decrease in supine systolic blood pressure
1
blood pressure
1
flow mediated dilatation
1
carotid femoral pulse wave velocity
1
visual persistence
1
reaction time
1
24h urine volume
1
oxygen consumption at 6 weeks
1
choice of treatment for use in the extension phase
1
choice of drug at visit 5
1
peak oxygen uptake during exercise
1
treatment related adverse events
1
progression free survival
1
recorded 2026-09-01 · last checked 2026-09-04
Q7
Which of Sildenafil's 26 ongoing trials reports first?
Perfused blood volume assessed pre and post sildenafil administration in susceptible smoker (SS) subjects.; Urinary Incontinence as measured by Pad Test; latest 2030-06-01
Show the evidence
Trial
NCT02682147
"Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema"; n 17; "Perfused blood volume assessed pre and post sildenafil administration in susceptible smoker (SS) subjects."; 2025-05
NCT02983461
"Use of Sildenafil for Treatment of Urinary Incontinence"; n 24; "Urinary Incontinence as measured by Pad Test"; 2028-07
NCT03686306
"VIRTUOSE : Efficiency of Sildenafil on the Absolute Claudication Distance of Peripheral Arterial Disease Patients With Intermittent Claudication."; n 106; "Absolute claudication distance"; 2026-06-24
NCT04565925
"Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries"; n 24; "Bladder Leakage as measured by 5 day bladder diary at Baseline"; 2026-12-01
NCT04797286
"Sildenafil for Early Pulmonary Vascular Disease in Scleroderma"; n 30; "Difference in change in distance walked in 6 minute walk test (6MWT) at 4 months"; 2026-09-01
NCT04898114
"Nebulized Magnesium Sulfate and Sildenafil for Persistent Pulmonary Hypertension of Newborn"; n 40; "Change in Oxygenation index (OI)"; 2025-06-01
14 further recorded trials
NCT05061368
"Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD"; n 160; "Exercise Capacity"; 2027-05
NCT05201144
"A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)"; n 40; "Change in Left Ventricular Eccentricity Index (LVEI) on echocardiogram after 14 days of study treatment compared to baseline echocardiogram as compared to placebo."; 2026-09-30
NCT05275725
"Finding Solutions to Thrive After Birth Asphyxia in Africa"; n 18; "Maximum tolerable dose of sildenafil"; 2025-01-31
NCT06098833
"Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia"; n 60; "Extent of brain injury"; 2028-06
NCT06123156
"Interest of Early Erectile Rehabilitation With Sildenafil After Radiotherapy and Proctectomy for Rectal Cancer"; n 188; "the patient's response"; 2030-02
NCT06510322
"Sildenafil to Reduce Vascular Remodeling During Left Ventricular Assist Device Support"; n 50; "Change in Aortic Pulse Wave Velocity"; 2029-12
NCT06649539
"Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease"; n 40; "Penile Curvature"; 2029-10
NCT06782659
"Study to Compare the Effects of Viagra® Vs Hezkue® in Healthy Fasted Male Participants."; n 56; "Cmax"; 2025-03
NCT06800092
"Sildenafil to Prevent and Reduce Cancer Related Cognitive Impairment"; n 30; "Fatigue and Cognition as measured by the Fatigue and Altered Cognition Scale at baseline"; 2030-06-01
NCT06810284
"Sildenafil Plus Hypothermia to Treat Neonatal Encephalopathy"; n 24; "Plasma concentrations of Sildenafil within the first 5 days following treatment initiation."; 2029-05
NCT06875258
"PEnile ReHABilitation After Nerve Sparing Robot-assisted Radical Prostatectomy for Prostate Cancer 2.0 (PEHAB-II)"; n 198; "Erectile function without tools"; 2027-01-01
NCT06954597
"Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis"; n 15; "Local treatment emergent adverse events (TEAEs)"; 2026-10-31
NCT07039760
"Asciminib With or Without Sildenafil for Brain Tumors"; n 12; "Tumor:plasma ratio of asciminib"; 2028-03-31
NCT07057011
"Therapeutic Outcomes of Selective Serotonin Reuptake Inhibitors and Phosphodiesterase-5 Inhibitors Combination Therapy Versus Monotherapy"; n 60; "Treatment of premature ejaculation"; 2026-02-10
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which running trial of Sildenafil could settle function?
NCT07462260 measures Change in 6-Minute Walk Distance (6MWD), reading out 2026-06.
2 open trials; n 100; "Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)"
Show the evidence
Trial
NCT07462260
"Sildinafil in Pulmonary Hypertension-Rheumatic Chronic Valvular Disease(RCT)"; n 100; "Change in 6-Minute Walk Distance (6MWD)"; 2026-06
NCT04797286
"Sildenafil for Early Pulmonary Vascular Disease in Scleroderma"; n 30; "Difference in change in distance walked in 6 minute walk test (6MWT) at 4 months"; 2026-09-01
Q9
Which 146 trials of Sildenafil posted no result?
Posted no result
146 of 146 completed trials
Registrations
NCT00420901, NCT00251784, NCT00527995, NCT00645034, NCT00654082 and NCT00644605, and 140 more
Completion dates
oldest 2000-02; newest 2024-07-05
Show the evidence
Trial
NCT00420901
2000-02
NCT00251784
2003-06
NCT00527995
2003-06
NCT00645034
2003-07
NCT00654082
2003-08
NCT00644605
2003-11
14 further recorded trials
NCT00644956
2003-11
NCT00645268
2004-01
NCT00746967
2004-02
NCT01941732
2004-03
NCT00644631
2004-04
NCT00547287
2004-05
NCT00648596
2004-05
NCT01616485
2004-05
NCT00159809
2004-08
NCT00547092
2004-11
NCT00407446
2005-02
NCT00654017
2005-04
NCT00143221
2005-05
NCT00375297
2005-06
Q10
At the median, Sildenafil's trials enrolled 40 people — anything larger?
Median enrolment
40
Largest enrolment
3337
Registered trials counted
365
Q11
What do 3416 spontaneous reports say about Sildenafil — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Sildenafil appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 3416 reaction mentions were counted: dyspnoea 747; headache 694; hypotension 412; condition aggravated 397. open-targets-adr · CHEMBL1737 · 2026-06-24
Show the evidence
dyspnoea
747
headache
694
hypotension
412
condition aggravated
397
flushing
230
visual impairment
213
4 more recorded rows
pulmonary hypertension
202
pulmonary arterial hypertension
183
nasal congestion
170
optic ischaemic neuropathy
168
recorded 2026-06-24 · last checked 2026-09-04
Q12
Sildenafil and CYP3A4, CYP2C9 and CYP2C19: shared by which compounds?
CYP3A4, CYP2C9 and CYP2C19 appear in Sildenafil's recorded interaction sentences, 19 in all. openfda-label+europepmc · 2026-08-30
In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg t.i.d.) with endothelin receptor antagonist bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19) at steady state (125 mg b.i.d.) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil C max .
CYP2C9
pharmacokinetics
Metabolism and Excretion: Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes.
pharmacokinetics
Drug Interaction Studies Effects of Other Drugs on sildenafil tablets Sildenafil metabolism is principally mediated by CYP3A4 (major route) and CYP2C9 (minor route).
pharmacokinetics
Pharmacokinetic data from patients in clinical trials showed no effect on sildenafil pharmacokinetics of CYP2C9 inhibitors (such as tolbutamide, warfarin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, ACE inhibitors, and calcium channel blockers.
pharmacokinetics
In vivo studies: No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9.
pharmacokinetics
In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg t.i.d.) with endothelin receptor antagonist bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19) at steady state (125 mg b.i.d.) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil C max .
CYP2D6pharmacokinetics
Pharmacokinetic data from patients in clinical trials showed no effect on sildenafil pharmacokinetics of CYP2C9 inhibitors (such as tolbutamide, warfarin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, ACE inhibitors, and calcium channel blockers.
CYP3A4
pharmacokinetics
It is eliminated predominantly by hepatic metabolism (mainly CYP3A4) and is converted to an active metabolite with properties similar to the parent, sildenafil.
pharmacokinetics
Metabolism and Excretion: Sildenafil is cleared predominantly by the CYP3A4 (major route) and CYP2C9 (minor route) hepatic microsomal isoenzymes.
pharmacokinetics
Drug Interaction Studies Effects of Other Drugs on sildenafil tablets Sildenafil metabolism is principally mediated by CYP3A4 (major route) and CYP2C9 (minor route).
pharmacokinetics
In a study of healthy male volunteers, sildenafil (100 mg) did not affect the steady state pharmacokinetics of the HIV protease inhibitors, saquinavir and ritonavir, both of which are CYP3A4 substrates.
pharmacokinetics
In a study of healthy male volunteers, co-administration of sildenafil at steady state (80 mg t.i.d.) with endothelin receptor antagonist bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of CYP2C19) at steady state (125 mg b.i.d.) resulted in a 63% decrease of sildenafil AUC and a 55% decrease in sildenafil C max .
pharmacokinetics
Concomitant administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in plasma levels of sildenafil.
6 more recorded rows
CYP3A4pharmacokinetics
The concomitant use of erythromycin or strong CYP3A4 inhibitors (e.g., saquinavir, ketoconazole, itraconazole) as well as the nonspecific CYP inhibitor, cimetidine, is associated with increased plasma levels of sildenafil [ see Dosage and Administration ( 2.4 ) ].
CYP3A4pharmacokinetics
When a single 100 mg dose of sildenafil citrate was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg bid for 5 days), there was a 160% increase in sildenafil C max and a 182% increase in sildenafil AUC.
CYP3A4pharmacokinetics
In addition, in a study performed in healthy male volunteers, co-administration of the HIV protease inhibitor saquinavir, also a CYP3A4 inhibitor, at steady state (1200 mg tid) with sildenafil tablets (100 mg single dose) resulted in a 140% increase in sildenafil C max and a 210% increase in sildenafil AUC.
CYP3A4pharmacokinetics
A stronger CYP3A4 inhibitor such as ketoconazole or itraconazole could be expected to have greater effect than that seen with saquinavir.
CYP3A4pharmacokinetics
Population pharmacokinetic data from patients in clinical trials also indicated a reduction in sildenafil clearance when it was co-administered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, or cimetidine) [ see Dosage and Administration ( 2.4 ) and Drug Interactions ( 7.4 ) ].
CYP3A4clinical_pharmacology
In the following patients: age >65 years, hepatic impairment (e.g., cirrhosis), severe renal impairment (e.g., creatinine clearance <30 mL/min), and concomitant use of erythromycin or strong CYP3A4 inhibitors, plasma levels of sildenafil at 24 hours post dose have been found to be 3 to 8 times higher than those seen in healthy volunteers.
recorded 2026-08-30 · last checked 2026-09-04
Q13
Was Sildenafil studied with exercise?
exercise is named in Sildenafil's label sentences: "Rest and exercise DL<sub>CO</sub> (cycle ergometry; 60 W, 30%, 60% and 90% of V̇O2peak$\dot{V}{{{\mathrm{O}}}_{2{\mathrm{peak}}}}$ ) was measured following oral sildenafil (50 mg) or placebo (block randomized) and evaluated using one-way ANOVA and linear mixed effects modelling." openfda-label+europepmc · 2026-08-30
1 recorded statement; exercise
Show the evidence
exercise
Rest and exercise DL<sub>CO</sub> (cycle ergometry; 60 W, 30%, 60% and 90% of V̇O2peak$\dot{V}{{{\mathrm{O}}}_{2{\mathrm{peak}}}}$ ) was measured following oral sildenafil (50 mg) or placebo (block randomized) and evaluated using one-way ANOVA and linear mixed effects modelling.
recorded 2026-08-30 · last checked 2026-09-04
Q14
What is recorded about Sildenafil and mTOR?
"Surprisingly, treatment with Sildenafil inhibited nitrosative stress and augmented the levels of LC3, beclin-1, ATG5, p-CREB and BDNF and decreased mTOR levels, as well as augmented p-AMPK." — where Sildenafil and mTOR appear together. Europe PMC · pathway abstract search · 2021-05-13
"Surprisingly, treatment with Sildenafil inhibited nitrosative stress and augmented the levels of LC3, beclin-1, ATG5, p-CREB and BDNF and decreased mTOR levels, as well as augmented p-AMPK."
AMPKPMID 34054847
"Surprisingly, treatment with Sildenafil inhibited nitrosative stress and augmented the levels of LC3, beclin-1, ATG5, p-CREB and BDNF and decreased mTOR levels, as well as augmented p-AMPK."
mTORPMID 34054847
"In conclusion, we propose that Sildenafil alleviates EAE by activating autophagy <i>via</i> the eNOS-NO-AMPK-mTOR-LC3-beclin1-ATG5 and eNOS-NO-AMPK-mTOR-CREB-BDNF pathways in the spinal cord."
AMPKPMID 34054847
"In conclusion, we propose that Sildenafil alleviates EAE by activating autophagy <i>via</i> the eNOS-NO-AMPK-mTOR-LC3-beclin1-ATG5 and eNOS-NO-AMPK-mTOR-CREB-BDNF pathways in the spinal cord."
autophagy
PMID 34054847
"In conclusion, we propose that Sildenafil alleviates EAE by activating autophagy <i>via</i> the eNOS-NO-AMPK-mTOR-LC3-beclin1-ATG5 and eNOS-NO-AMPK-mTOR-CREB-BDNF pathways in the spinal cord."
PMID 31777946
"The aim of this study is to investigate cadmium-induced adrenal cortical autophagy and to declare possible modulation by sildenafil."
PMID 31777946
"Sildenafil taken with cadmium had decreased adrenal cortical autophagy, significantly modulated the adrenal gland superoxide dismutase and malondialdehyde compared to cadmium group."
sirtuinPMID 32467879
"Integrating previous findings, we determine that most doses of sildenafil (especially low doses) likely activate peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α) via protein kinase G-mediated cyclic adenosine monophosphate (cAMP) response element binding protein (CREB) phosphorylation and/or Sirtuin-1 activation and PGC1α deacetylation."
AMPKPMID 27903966
"Pemetrexed reduced the ATPase activities of HSP90 and HSP70 in an ATM-AMPK-dependent fashion that was enhanced by sildenafil signaling via PKGI/II."
sirtuin
PMID 28042486
"L-leucine, an allosteric Sirt1 activator, synergizes with low doses of metformin or sildenafil on the AMPK-eNOS-Sirt1 pathway to reverse mild NAFLD in preclinical mouse models."
PMID 28974454
"This work aimed to investigate the possible protective effect of sildenafil (SIRT1 activator) against hepatic fibrosis induced by bile duct ligation (BDL)."
mTORPMID 30203445
"Compared with [regorafenib + sildenafil], the three-drug combination caused greater and more prolonged activation of the ATM-AMPK-ULK-1 pathway and caused a greater suppression and prolonged inactivation of mammalian target of rapamycin, AKT, and p70 S6K."
recorded 2021-05-13 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 11 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.